Uncontrolled hypertension is associated with coronary artery calcification and electrocardiographic left ventricular hypertrophy: A case-control study

Journal of Human Hypertension

Volumn 29, Issue 5, 2015, Pages 303-308

  Nielsen, M L ^a   Pareek, M ^a   Gerke, O ^a   Diederichsen, S Z ^a   Greve, S V ^a   Blicher, M K ^a   Sand, N P R ^b   Mickley, H ^a   Diederichsen, A C P ^a   Olsen, M H ^a,c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

^c NORTH WEST UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; UNCONTROLLED HYPERTENSION; AGED; CALCINOSIS; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DENMARK; DRUG RESISTANCE; HYPERTROPHY, LEFT VENTRICULAR; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOGRAPHY; RISK FACTOR; STATISTICS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CALCINOSIS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY VESSELS; DENMARK; DRUG RESISTANCE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTORS; STATISTICS AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927797978     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.88     Document Type: Article

References (35)

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13): 1635-1701.
2. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987-1003.
3. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-1847.
4. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010; 56(17): 1397-1406.
5. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114(16): 1761-1791.
6. Erbel R, Lehmann N, Möhlenkamp S, Churzidse S, Bauer M, Kälsch H et al. Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the Heinz Nixdorf Recall Study. Hypertension 2012; 59(1): 44-53.
7. Bonow RO. Clinical practice. Should coronary calcium screening be used in cardiovascular prevention strategies? New Engl J Med 2009; 361(10): 990-997.
8. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-2219.
9. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90(4): 1786-1793.
10. Diederichsen SZ, Gerke O, Olsen MH, Lambrechtsen J, Sand NP, Nørgaard BL et al. Coronary artery calcification and ECG pattern of left ventricular hypertrophy or strain identify different healthy individuals at risk. J Hypertens 2013; 31(3): 595-600.
11. Diederichsen AC, Sand NP, Nørgaard B, Lambrechtsen J, Jensen JM, Munkholm H et al. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. Eur J Prev Cardiol 2012; 19(3): 558-564.
12. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15(4): 827-832.
13. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003; 228(3): 826-833.
14. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004; 164(12): 1285-1292.
15. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 2007; 115(3): 402-426.
16. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37(2): 161-186.
17. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992; 20(5): 1180-1186.
18. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25(2): 417-423.
19. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960; 21: 1160-1175.
20. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000; 56(2): 645-646.
21. Allen NB, Siddique J, Wilkins JT, Shay C, Lewis CE, Goff DC et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA 2014; 311(5): 490-497.
22. Barrios V, Escobar C, Calderon A, Ribas L, Marti D, Asin E. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press 2008; 17(2): 110-115.
23. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. New Engl J Med 2008; 358(13): 1336-1345.
24. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010; 303(16): 1610-1616.
25. Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes 2014; 7(3): 453-460.
26. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
27. Norman JE Jr, Levy D. Improved electrocardiographic detection of echocardio-graphic left ventricular hypertrophy: results of a correlated data base approach. J Am Coll Cardiol 1995; 26(4): 1022-1029.
28. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 1987; 75(3): 565-572.
29. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32(6): 989-997.
30. Chou R, Arora B, Dana T, Fu R, Walker M, Humphrey L. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155(6): 375-385.
31. Fagard RH, Staessen JA, Thijs L, Celis H, Birkenhäger WH, Bulpitt CJ et al. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004; 44(4): 459-464.
32. Auer R, Bauer DC, Marques-Vidal P, Butler J, Min LJ, Cornuz J et al. Association of major and minor ECG abnormalities with coronary heart disease events. J Am Med Assoc 2012; 307(14): 1497-1505.
33. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. J Am Med Assoc 2004; 292(19): 2343-2349.
34. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 2014; 383(9932): 1912-1919.
35. Myers MG. Eliminating the human factor in office blood pressure measurement. J Clin Hypertens (Greenwich) 2014; 16(7): 541-542.